| Aug 12 |
Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.12M misses by $1.51M
|
| Aug 12 |
Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights
|
| Aug 12 |
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript
|
| Aug 12 |
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 12 |
Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.11M misses by $1.52M
|
| Aug 12 |
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 11 |
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has caught the attention of institutional investors who hold a sizeable 46% stake
|
| Aug 5 |
Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
|
| Jul 5 |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Jul 1 |
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
|
